DHODH and acute myeloid leukemia: Based on a number of promising preclinical studies, clinical trials on DHODH inhibition were initiated to leverage this selective vulnerability in AML cells, but at least two of these trials BAY2402234 (NCT03404726 – terminated due to limited efficacy) or with PTC299 (NCT03761069) have been discontinued.